Amerisourcebergen Drug Corp

Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., operates as a pharmaceutical distributor and medical supplier delivering brand-name and generic medications, specialty pharmaceuticals, vaccines, and medical devices to the Department of Defense and federal healthcare systems as a prime contractor on full-and-open competitive awards. The company competes without set-asides and holds a single-award indefinite delivery contract (SPE2DX) with the Defense Logistics Agency valued at $4.999 million through December 2036, supporting the Pharmaceutical Prime Vendor Global Program Generation V for worldwide military healthcare supply across multiple therapeutic domains.

Amerisourcebergen's federal footprint is dominated by transactional pharmaceutical delivery orders under the DLA Troop Support Medical IDC and broader DLA procurement vehicles. Recent representative work includes a $28 thousand medical supplies delivery order from the FBI Academy (July 1, 2026), firm fixed-price delivery orders for epinephrine auto-injectors ($43,684.93), Dupixent injectables ($14,485.35 and $19,400.92), Mounjaro diabetes medications ($16,120.17 and $18,855.89), Zepbound weight-loss injectables (multiple orders totaling $88,000 combined), and bulk pharmaceutical shipments to the DLA Medical Supply Chain ($3.104 million and $2.019 million orders in April 2026). The company supplies controlled substances, specialty injectables, vaccines, diagnostics, and ancillary medical materials across Defense Health Agency, Coast Guard, and subordinate military medical facilities globally.

The Defense Logistics Agency dominates customer concentration, accounting for the vast majority of award count and dollar value across its Troop Support Medical and general procurement lines. Over the past five years (2022–2026), activity has remained consistent at roughly 390,000 to 500,000 annual awards, reflecting continuous transactional purchasing rather than growth or contraction. The combined potential value across all awards in the source data reaches $1.488 trillion, though only 4 percent has been obligated to date ($61.88 billion), indicating the portfolio consists primarily of delivery-order ceilings under standing IDCs rather than executed spend. The recompete cliff shows minimal exposure—only one award ($28 thousand) matures in the next twenty-four months, reflecting the long-tail structure of indefinite delivery contracts running through 2026–2036.

Amerisourcebergen holds position on five top parent vehicles, all DLA Troop Support Medical SPE2DX-series indefinite delivery contracts: SPE2DX15D1053 (82,481 task orders, $784 million potential), SPE2DX15D1022 (77,047 task orders, $993.3 million potential), SPE2DX15D2206 (69,342 task orders, $908.8 million potential), SPE2DX15D1106 (67,841 task orders, $422.8 million potential), and SPE2DB20D1100 (65,297 task orders, $435.3 million potential). The company is categorized under NAICS 424210 (Drugs and Druggists' Sundries Merchant Wholesalers) and PSC code 6515, with secondary NAICS coverage in pharmaceutical and medicinal manufacturing. No subcontract work appears in the recent award set. Cencora, Inc., the parent company, holds broader federal contract positions as a prime across civilian and defense health programs; Amerisourcebergen Drug Corp operates as the execution entity for DLA pharmaceutical distribution within that parent structure.